Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
11/15/2021 - 07:30 AM
RADNOR, Pa. --(BUSINESS WIRE)--
Marinus Pharmaceuticals, Inc.
12th Annual Jefferies London Healthcare Conference
Date and Time: Available on demand starting Thursday, November 18 , 3:00 a.m. ET through Friday, November 19 , 12:00 p.m. ET
Speakers: Scott Braunstein , M.D., Chief Executive Officer and Steven Pfanstiel , Chief Financial Officer
Webcast Link: https://wsw.com/webcast/jeff201/mrns/1865664
Marinus Pharmaceuticals Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting
Jefferies Denver Healthcare Summit
Date and Time: Thursday, December 16
One-on-one meetings with Marinus leadership open only to Jefferies conference participants
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year, is planning to conduct a Phase 3 trial in tuberous sclerosis complex, and a Phase 3 trial in refractory status epilepticus is ongoing. For more information visit www.marinuspharma.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20211115005040/en/
Sasha Damouni Ellis
Marinus Pharmaceuticals, Inc.
sdamouni@marinuspharma.com
Source: Marinus Pharmaceuticals
Marinus Pharmaceuticals Inc
MRNS Rankings
#1099 Ranked by Stock Gains
MRNS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
About MRNS
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
